Schistosomiasis Treatment Market

Schistosomiasis Treatment Market Overview

The disease caused by parasitic worms is often known as schistosomiasis, and the treatment associated with is known as schistosomiasis treatment. Also known as bilharzia, the acute and chronic parasitic disease is caused by blood flukes of the genus Schistosoma. Increasing prevalence of schistosomiasis among individuals worldwide and therefore the need for preventive treatment or the disease is one of the major factors predicted to drive the growth of the schistosomiasis treatment market during the forecast period. Mylan N.V., Teva Pharmaceutical Industries Ltd, and Sanofi are some of the significant parties in the market for schistosomiasis treatment.

The global schistosomiasis treatment market was valued at USD 76.4 million in 2023. The market is expected to expand at a CAGR of 4.3% from 2023-2032, and is expected to cross value of USD 103.7 million by the end of 2032.

Schistosomiasis Treatment Market Drivers

Some key drivers for the schistosomiasis treatment market are:

• Rising Need for Preventive Treatment: The rise in awareness for different types of diseases among individuals raises the need for preventive treatment. In a similar fashion, with the growing prevalence of schistosomiasis disease, the need for preventive treatment among individuals is on the rise, which is expected to boost the market growth forward.
• Growing Demand for Oral Drugs: Oral drugs are always an easy way of administrating any drug when compared to other route of drug administration. Hence, the rise in demand for oral drugs also poses a marvellous opportunity for the expansion of the market in the coming years.
• Increasing Development of Novel Vaccines: The manufacturers of pharmaceutical drugs around the globe are increasingly working on developing novel vaccines for different diseases. As such, for the treatment of schistosomiasis disease, pharmaceutical drug manufacturers are increasingly working on developing advanced drugs, which in turn, is projected to boost the growth of the market.
• Rising Healthcare Awareness Among Individuals: The government of nations worldwide are increasingly working upon raising awareness related to different types of diseases and also are promoting measures to maintain good health. As such, the treatment of schistosomiasis is also on this list of diseases for which awareness programs are being offered. Such a factor is also projected to push the market growth forward.

                                     Get More Insights on This Report - Request Free Sample PDF

Schistosomiasis Treatment Market Challenges

Some challenges facing the schistosomiasis treatment market are:

• Lack of Skilled Surgeons: The unavailability of skilled surgeons in several nations globally for treating schistosomiasis is one of the major factors expected to limit the growth of the market in the coming years.
• High Cost of Treatment: The high cost of treating schistosomiasis, as a result of high price of the drugs needed to treat the disease, is also poised to lower the market growth.
• Lack of Awareness for the Unavailability of Treatment for Schistosomiasis: Several nations worldwide still do not have access to quality information for the treatment of several diseases, one of which include the treatment for schistosomiasis. Such a factor is hence projected to hamper the market growth during the forecast period.

Schistosomiasis Treatment Market Segmentation

Segmentation of schistosomiasis treatment market are:

• By Type
  • Schistosoma mansoni
  • Schistosoma japonicum
  • Others
• By Drugs
  • Praziquantel
  • Metrifonate
  • Oxamniquine
  • Others
• By Route of Administration
  • Oral
  • Topical
  • Others
• By End Users
  • Hospitals Homecare
  • Specialty centers
  • Others
• By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
• By Region:
  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa

Timeline considered for all these studies will be:

2023 – Base Year

2023 – Estimated Year

2023-2032 – Forecast Period

Schistosomiasis Treatment Market Regional Synopsis

The availability of skilled surgeons, along with the presence of a strong healthcare network are some of the major factors predicted to help the North American schistosomiasis treatment market grab the largest market share by the end of 2032. Further, the market in the region is also expected to grow on account of the growing demand for disease-specific treatment and high level of awareness amongst patients for treating the disease.

Moreover, the Asia Pacific schistosomiasis treatment market is expected to grow, supported by the rise in the number of generic drug manufacturers in this region, followed by the increasing awareness for the treatment of the disease in several nations.

Schistosomiasis Treatment Market Key Players

Some key players in the schistosomiasis treatment market are:

• Mylan N.V.
• Teva Pharmaceutical Ltd.
• Sanofi
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Eliu Lilly and Company
• Merck & Co., Inc.
• AbbVie Inc.
• Johnson & Johnson Private Limited
• Cipla Inc.
• AstraZeneca
• Abbott
• Bausch Health Companies Inc
• Sun Pharmaceutical Industries Ltd.